Original Article

You have full text access to this OnlineOpen article

Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein β1 gene CTNNB1 for patients with Wilms tumors†

Results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology

  1. Brigitte Royer-Pokora PhD1,‡,*,
  2. Angela Weirich MD2,
  3. Valerie Schumacher PhD1,
  4. Constanze Uschkereit MS1,
  5. Manfred Beier BE1,
  6. Ivo Leuschner MD3,
  7. Norbert Graf MD4,
  8. Frank Autschbach MD5,
  9. Dominique Schneider MD6,
  10. Melissa von Harrach MS1

Article first published online: 10 JUL 2008

DOI: 10.1002/cncr.23672

Issue

Cancer

Cancer

Volume 113, Issue 5, pages 1080–1089, 1 September 2008

Additional Information

How to Cite

Royer-Pokora, B., Weirich, A., Schumacher, V., Uschkereit, C., Beier, M., Leuschner, I., Graf, N., Autschbach, F., Schneider, D. and von Harrach, M. (2008), Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein β1 gene CTNNB1 for patients with Wilms tumors. Cancer, 113: 1080–1089. doi: 10.1002/cncr.23672

Author Information

  1. 1

    Institute of Human Genetics and Anthropology, Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany

  2. 2

    Department of Pediatric Hematology and Oncology, Children's Hospital, University of Heidelberg, Heidelberg, Germany

  3. 3

    Institute of Pediatric Pathology, University of Kiel, Kiel, Germany

  4. 4

    Department of Pediatric Hematology and Oncology, Children's Hospital, University of the Saarland, Homburg, Germany

  5. 5

    Department of General Pathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany

  6. 6

    Department of Pediatric Hematology and Oncology, Children's Hospital, Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany

  1. ‡

    Fax: (011) 49 211 8112538;

*Institute of Human Genetics and Anthropology, Heinrich-Heine University of Duesseldorf, Postfach 101007, D40001 Duesseldorf, Germany

  1. †

    See editorial on pages 893-6, this issue.

Publication History

  1. Issue published online: 20 AUG 2008
  2. Article first published online: 10 JUL 2008
  3. Manuscript Accepted: 13 FEB 2008
  4. Manuscript Revised: 11 FEB 2008
  5. Manuscript Received: 10 OCT 2007

Funded by

  • Elterninitiative Kinderkrebsklinik e.V., Duesseldorf

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (229K)

REFERENCES

  • 1
    Tournade MF,Com-Nougue C,de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol. 2001; 19: 488–500.
  • 2
    Vujanic GM,Sandstedt B,Harms D,Kelsey A,Leuschner I,de Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol. 2002; 38: 79–82.
    Direct Link:
  • 3
    Weirich A,Ludwig R,Graf N, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol. 2004; 15: 808–820.
  • 4
    Egeler RM,Wolff JE,Anderson RA,Coppes MJ. Long-term complications and post-treatment follow-up of patients with Wilms' tumor. Semin Urol Oncol. 1999; 17: 55–61.
  • 5
    Oeffinger KC,Mertens AC,Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355: 1572–1582.
  • 6
    Weirich A,Leuschner I,Harms D, et al. Clinical impact of histologic subtypes in localized nonanaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol. 2001; 12: 311–319.
  • 7
    Saba LM,de Camargo B,Gabriel-Arana M. Experience with six children with fetal rhabdomyomatous nephroblastoma: review of the clinical, biologic, and pathologic features. Med Pediatr Oncol. 1998; 30: 152–155.
    Direct Link:
  • 8
    Maes P,Delemarre J,de Kraker J,Ninane J. Fetal rhabdomyomatous nephroblastoma: a tumour of good prognosis but resistant to chemotherapy. Eur J Cancer. 1999; 35: 1356–1360.
  • 9
    Pollono D,Drut R,Tomarchio S,Fontana A,Ibanez O. Fetal rhabdomyomatous nephroblastoma: report of 14 cases confirming chemotherapy resistance. J Pediatr Hematol Oncol. 2003; 25: 640–643.
  • 10
    Anderson J,Slater O,McHugh K,Duffy P,Pritchard J. Response without skrinkage in bilateral Wilms tumor: significance of rhabdomyomatous histology. J Pediatr Hematol Oncol. 2002; 24: 31–34.
  • 11
    Schumacher V,Schneider S,Figge A, et al. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA. 1997; 94: 3972–3977.
  • 12
    Shibata R,Hashiguchi A,Sakamoto J,Yamada T,Umezawa A,Hata J. Correlation between a specific Wilms tumour suppressor gene (WT1) mutation and the histological findings in Wilms tumour (WT). J Med Genet [serial online]. 2002; 39: e83.
  • 13
    Little SE,Hanks SP,King-Underwood L, et al. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group study. J Clin Oncol. 2004; 22: 4140–4146.
  • 14
    Fukuzawa R,Heathcott RW,Sano M,Morison IM,Yun K,Reeve AE. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol. 2004; 7: 125–137.
  • 15
    Schumacher V,Schuhen S,Sonner S, et al. Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin Cancer Res. 2003; 9: 2005–2014.
  • 16
    Nakadate H,Yokomori K,Watanabe N, et al. Mutations/deletions of the WT1 gene, loss of heterozygosity on chromosome arms 11p and 11q, chromosome ploidy and histology in Wilms' tumors in Japan. Int J Cancer. 2001; 94: 396–400.
    Direct Link:
  • 17
    Kalapurakal JA,Dome JS,Perlman EJ, et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 2004; 5: 37–46.
  • 18
    Schumacher V,Scharer K,Wuhl E, et al. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int. 1998; 53: 1594–1600.
  • 19
    Koesters R,Ridder R,Kopp-Schneider A, et al. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999; 59: 3880–3882.
  • 20
    Coppes MJ,Arnold M,Beckwith JB, et al. Factors affecting the risk of contralateral Wilms tumor development. Cancer. 1999; 85: 1616–1625.
    Direct Link:
  • 21
    Royer-Pokora B,Beier M,Henzler M, et al. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet. 2004; 127A: 249–257.
    Direct Link:
  • 22
    Beckwith JB. Nephrogeneic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet. 1998; 79: 268–273.
    Direct Link:
  • 23
    Fukuzawa R,Heathcott RW,More HE,Reeve A. Sequential WT1 and CTNNB1 mutations and alterations of β-catenin localisation in intralobar nephrogenic rests and associated Wilms tumors: two case studies. J Clin Pathol. 2007; 60: 1013–1016.
  • 24
    Shamberger RC,Haase GM,Argani P, et al. Bilateral Wilms' tumors with progressive or nonresponsive disease. J Pediatr Surg. 2006; 41: 652–657.
  • 25
    Uschkereit C,Perez N,de Torres C,Kuff M,Mora J,Royer-Pokora B. Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumors in a patient with a novel germ line WT1 mutation. J Med Genet. 2007; 44: 393–396.
  • 26
    Rohrschneider WK,Weirich A,Rieden K,Darge K,Troger J,Graf N. US, CT and MR imaging characteristics of nephrobalstomatosis. Pediatr Radiol. 1998; 28: 435–443.
  • 27
    Shibata R,Takata A,Hashiguchi A,Umezawa A,Yamada T,Hata J. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor. Pathol Int. 2003; 53: 214–220.
    Direct Link:
  • 28
    Zirn B,Samans B,Wittmann S, et al. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer. 2006; 45: 565–574.
    Direct Link:
  • 29
    Li CM,Kim CE,Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol. 2004; 165: 1943–1953.
View Full Article (HTML) Get PDF (229K)